Zelira Therapeutics (ZLDAF) Stock Price, News & Analysis

Company Overview

Zelira Therapeutics Ltd is a clinical-stage biotechnology company focused on the development and commercialization of proprietary cannabinoid-based therapies. The company leverages a portfolio of clinical and preclinical drug candidates designed to address unmet medical needs in areas such as chronic pain, autism spectrum disorder, Alzheimer’s disease and sleep disorders. Utilizing patented formulation and delivery platforms, Zelira aims to optimize efficacy and safety profiles of plant-derived cannabinoids.

The company pursues a dual geography strategy through its Australian and North American operations. In Australia, Zelira Therapeutics collaborates with academic and research institutions to advance clinical trials and regulatory approvals. In North America, the company engages with strategic partners, healthcare providers and regulatory bodies to progress its lead programs toward commercialization. Key products in development include gel formulations, oral capsules and transdermal patches tailored for pediatric and adult patient populations.

Zelira’s product pipeline encompasses both prescription-focused drug candidates and wellness offerings. Its clinical portfolio includes novel cannabinoid combinations targeting neurodevelopmental conditions, while early-stage research explores formulations for mood and cognitive disorders. The company’s R&D efforts are underpinned by expertise in pharmacology, formulation science and regulatory strategy, with a focus on achieving scalable manufacturing and global market access.

Headquartered in Melbourne, Australia, Zelira Therapeutics was founded to bridge the gap between botanical science and pharmaceutical-grade products. The executive team combines experience in biotech innovation, clinical development and commercial operations. Through ongoing trials, strategic collaborations and regulatory engagements, Zelira aims to establish itself as a leader in cannabinoid therapeutics for both medical and wellness markets.

Key Stats

• Today's Range: $0.21 to $0.21
• 50-Day Range: $0.21 to $0.30
• 52-Week Range: $0.21 to $0.49
• Volume: 165 shs
• Average Volume: 520 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ZLDAF Stock Analysis - Frequently Asked Questions

How have ZLDAF shares performed this year?

Zelira Therapeutics' stock was trading at $0.3830 at the start of the year. Since then, ZLDAF shares have decreased by 43.9% and is now trading at $0.2149.

When did Zelira Therapeutics' stock split?

Shares of Zelira Therapeutics reverse split before market open on Monday, April 18th 2022.The 1-175 reverse split was announced on Monday, April 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Zelira Therapeutics?

Shares of ZLDAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ZLDAF
• CIK: N/A
• Web: www.zeldatherapeutics.com
• Phone: (186) 558-0886
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A